SHP639 (n=60)

Phase 1Small molecule

Takeda

SHP639 (n=60) is one of 31 small molecule programs targeting Open-Angle Glaucoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Open-Angle GlaucomaActive, not recruiting

Open-Angle GlaucomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Open-Angle Glaucoma

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

1 2

Travatan

Zolymbus

Namenda

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 6

Isopto Carpine

AAdvanz Pharma

Approved

—7

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Adrucil

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Mitosol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Open-Angle Glaucoma1 trial

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

Completed· Takeda logo

Takeda·Phase 1·NCT03131167·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SHP639 (n=60). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHP639 (n=60) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHP639 (n=60). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Takeda

SHP639 (n=60)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Open-Angle Glaucoma1 trial

References

Drug Info

Quick Facts

Related News